Topotecan
Small molecule targets HIF1A, TOP1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TOPOTECAN HYDROCHLORIDE | — | 2017-09-20 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | HYCAMTIN | — | 1998-11-30 – 2006-06-14 | fda.gov ↗ |
| Approved | EU (EMA) | Hycamtin | — | 1996-11-12 | europa.eu ↗ |
| Approved | US (FDA) | HYCAMTIN | — | 1996-05-28 | fda.gov ↗ |
Trials 316 · started per year
Also used as a comparator or background therapy in 137 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 120 trials | ||||||
| Phase 1 | NCT06930755 Background | May 2026 → May 2027 expected | ovarian cancer | Nerviano Medical Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT05990738 Background | Feb 2024 → Mar 2027 expected | small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05521984 Background | Apr 2023 → Mar 2031 expected | brain cancer, childhood malignant neoplasm | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05421897 Background | Nov 2022 → Jan 2026 overdue | neuroblastoma | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04022876 Background | Sep 2019 → Jul 2022 | non-small cell lung carcinoma, small cell lung carcinoma | Aileron Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03763123 Background | Apr 2018 → Dec 2019 | ovarian cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03236857 Background | Nov 2017 → Apr 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03107988 Background | Sep 2017 → Aug 2024 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT02298348 Background | Oct 2015 → Dec 2026 expected | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02419495 Background | Jun 2015 → Sep 2024 | cutaneous melanoma, fallopian tube carcinoma, metastatic malignant neoplasm, metastatic melanoma +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02390843 Background | Feb 2015 → Sep 2019 | Ewing sarcoma, Wilms tumor, clear cell sarcoma, germ cell tumor +7 | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01606878 Background | Apr 2013 → Dec 2018 | anaplastic large cell lymphoma, childhood malignant neoplasm, neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01798004 Background | Apr 2013 → Jul 2015 | ganglioneuroblastoma, neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01576692 Background | Apr 2012 → Oct 2014 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00877110 Background | Apr 2009 → Jan 2019 | bone marrow disorder, neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00682279 Comparator | Sep 2008 → Mar 2011 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT00588991 Background | Feb 2008 → Nov 2016 | acquired polycythemia vera, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +13 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00881166 Background | Nov 2007 → Dec 2009 | cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00462787 Background | Apr 2007 → Nov 2013 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00466232 Background | Apr 2007 → Dec 2009 | lung cancer, small cell carcinoma | HealthPartners Institute | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT07437963 Background | Jul 2026 → Sep 2029 expected | ganglioneuroblastoma, neuroblastoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07141771 Background | Dec 2025 → Jun 2030 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07334301 Background | Nov 2024 → Dec 2030 expected | neuroblastoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05652686 Background | Sep 2023 → Dec 2027 expected | digestive system neuroendocrine neoplasm, large cell neuroendocrine carcinoma, prostate neuroendocrine neoplasm, small cell lung carcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05266196 Background | Jan 2022 → Dec 2025 | Ewing sarcoma, clear cell sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma +4 | Salarius Pharmaceuticals, LLC | Unknown | No outcome recorded |
| Phase 1/2 | NCT04029688 Background | Jan 2020 → May 2024 | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT01076400 Background | May 2010 → Jun 2011 | cervical cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00521144 Background | Aug 2007 → Aug 2010 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT07321912 Background | Jun 2026 → Jun 2031 expected | Ewing sarcoma, osteosarcoma | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06933394 Background | May 2025 → May 2031 expected | neuroblastoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06861244 Background | Mar 2025 → Sep 2030 expected | embryonal tumor with multilayered rosettes | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT06449209 Background | Aug 2024 → Jun 2027 expected | small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05295589 Comparator | Jun 2022 → Mar 2023 | fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma +1 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT04739800 Comparator | Jun 2021 → Jan 2023 overdue | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +9 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04768296 Background | Mar 2021 → Jul 2023 | small cell lung carcinoma | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04213937 Comparator | Jan 2020 → Jul 2021 | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03699449 Background | Nov 2018 → Sep 2022 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT03289910 Background | Sep 2018 → May 2023 overdue | acquired polycythemia vera, acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia +2 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02963090 Comparator | May 2017 → Jun 2019 | small cell lung carcinoma | Alliance Foundation Trials, LLC. | Terminated | No outcome recorded |
| Phase 2 | NCT03059667 Comparator | Mar 2017 → Sep 2018 | small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2 | NCT02980809 Background | Mar 2017 → Mar 2019 | small cell lung carcinoma | First Hospitals affiliated to the China PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02822157 Comparator | Aug 2016 → Jul 2021 | malignant epithelial tumor of ovary | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| Phase 2 | NCT02200757 Comparator | Apr 2015 → May 2017 | small cell lung carcinoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02866370 Comparator | Apr 2015 → Mar 2020 | endometrial clear cell adenocarcinoma, ovarian clear cell cancer | NHS Greater Glasgow and Clyde | Unknown | No outcome recorded |
| Phase 2 | NCT02364713 Comparator | Mar 2015 → Jan 2022 | fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma +11 | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT02114229 Background | May 2014 → Sep 2025 overdue | atypical teratoid rhabdoid tumor | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02107378 Comparator | Jan 2014 → Aug 2016 | malignant epithelial tumor of ovary | SOTIO a.s. | Terminated | No outcome recorded |
| Phase 2 | NCT01857934 Background | Jul 2013 → Oct 2021 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01904253 Comparator | Jul 2013 → Jun 2014 | small cell lung carcinoma | Taiho Oncology, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01803269 Comparator | Jan 2013 → Mar 2016 | small cell lung carcinoma | University of Chicago | Terminated | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01500720 Comparator | Mar 2012 → Apr 2014 | small cell lung carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01533181 Comparator | Feb 2012 → Nov 2014 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01492673 Background | Dec 2011 → Oct 2018 | neuroblastoma, sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01630018 Comparator | Jan 2011 → Jun 2014 | malignant epithelial tumor of ovary | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT01497873 Comparator | Sep 2010 → Dec 2017 | small cell lung carcinoma | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT01121406 Comparator | Apr 2010 → Jun 2014 | ovarian neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01047891 Background | Jan 2010 → Feb 2015 | ovarian cancer | JSehouli | Completed | No outcome recorded |
| Phase 2 | NCT00808899 Background | Dec 2008 → Jul 2009 | neuroblastoma | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00516295 Background | Feb 2008 → Aug 2009 | Ewing sarcoma of bone, extraskeletal Ewing sarcoma, peripheral primitive neuroectodermal tumor | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00601003 Background | Jan 2008 → Apr 2020 | medulloblastoma, neuroblastoma | Giselle Sholler | Completed | No outcome recorded |
| Phase 2 | NCT00319969 Comparator | Apr 2006 → Jul 2008 | small cell lung carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00170677 Comparator | Sep 2005 → Jan 2013 | ovarian cancer | North Eastern German Society of Gynaecological Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00114166 Comparator | Jan 2005 → Jan 2011 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00744081 Background | Jul 2004 → Dec 2010 | acute myeloid leukemia | Goethe University | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07106528 Comparator | Aug 2025 → Dec 2027 expected | small cell lung carcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06161025 Comparator | Feb 2024 → Feb 2028 expected | — | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05870748 Comparator | Jul 2023 → Aug 2025 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sutro Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT03651206 Comparator | Jul 2020 → Jun 2027 expected | ovarian carcinosarcoma, uterine carcinosarcoma | ARCAGY/ GINECO GROUP | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03098030 Comparator | Jun 2017 → Jan 2020 | small cell lung carcinoma | United Therapeutics | Completed | No outcome recorded |
| Phase 2/3 | NCT02502266 Comparator | May 2016 → Jun 2023 overdue | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma +7 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02101788 Comparator | Apr 2014 → Apr 2019 | borderline ovarian serous tumor, micropapillary serous carcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 364 trials | ||||||
| Phase 3 | NCT07708753 Comparator | Jul 2026 → Oct 2029 expected | fallopian tube cancer, primary peritoneal carcinoma, refractory malignant neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07545460 Comparator | Jul 2026 → Dec 2028 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07286266 Comparator | Jun 2026 → Dec 2029 expected | ovarian neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07604766 Comparator | Jun 2026 → Sep 2027 expected | refractory malignant neoplasm | Genmab | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07546500 Comparator | Apr 2026 → May 2028 expected | ovarian cancer | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT07365241 Comparator | Apr 2026 → Sep 2030 expected | small cell lung carcinoma | AbbVie | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07418749 Comparator | Mar 2026 → Dec 2027 expected | cervical cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07218809 Comparator | Dec 2025 → Nov 2028 expected | ovarian epithelial tumor | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07189455 Comparator | Dec 2025 → Oct 2028 expected | small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07218146 Comparator | Nov 2025 → Jun 2028 expected | small cell lung carcinoma | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07230626 Comparator | Nov 2025 → Jan 2028 expected | cervical cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07213804 Comparator | Oct 2025 → Nov 2028 expected | fallopian tube neoplasm, metastatic neoplasm, ovarian neoplasm, peritoneal neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07099898 Comparator | Aug 2025 → Nov 2027 expected | lung neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06994195 Comparator | Aug 2025 → Jun 2027 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06954246 Comparator | Jun 2025 → May 2027 expected | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06990503 Comparator | Jun 2025 → Jun 2030 expected | ovarian cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06855069 Comparator | Mar 2025 → Mar 2027 expected | ovarian carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06828354 Comparator | Mar 2025 → May 2027 expected | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06619236 Comparator | Feb 2025 → Feb 2027 expected | refractory malignant neoplasm | Genmab | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06751485 Comparator | Jan 2025 → Dec 2026 expected | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06612151 Comparator | Dec 2024 → Dec 2027 expected | small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06616532 Comparator | Nov 2024 → Jan 2027 expected | small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06581380 Comparator | Sep 2024 → Nov 2027 expected | small cell lung carcinoma | JenKem Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06496048 Comparator | Sep 2024 → Dec 2027 expected | small cell lung carcinoma | Luye Pharma Group Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06692166 Comparator | Sep 2024 → Dec 2027 expected | cervical cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06459180 Comparator | Jul 2024 → Jun 2028 expected | cervical cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06498479 Comparator | Jul 2024 → Sep 2026 expected | small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06203210 Comparator | May 2024 → Apr 2027 expected | small cell lung carcinoma | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 3 | NCT06394492 Comparator | May 2024 → May 2026 overdue | ovarian cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06172296 Background | Apr 2024 → Dec 2029 expected | neuroblastoma, nodular ganglioneuroblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06128837 Comparator | Mar 2024 → Jun 2028 expected | small cell lung carcinoma | Luye Pharma Group Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05740566 Comparator | May 2023 → Jan 2025 overdue | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05153239 Comparator | Jul 2022 → Apr 2026 | small cell lung carcinoma | PharmaMar | Completed | No outcome recorded |
| Phase 3 | NCT05092360 Comparator | Jan 2022 → Jan 2025 | fallopian tube carcinoma, primary peritoneal carcinoma, refractory malignant neoplasm | Mural Oncology, Inc | Terminated | No outcome recorded |
| Phase 3 | NCT04943627 Comparator | Aug → Oct 2021 | cancer of unknown primary site, cervical cancer | Agenus Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04908787 Background | Jun 2021 → Dec 2023 | ovarian cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04902885 Comparator | May → Dec 2021 | small cell lung carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04799002 Comparator | Mar 2021 → Dec 2024 overdue | chemotherapy-induced toxicity, retinoblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT04697628 Comparator | Feb 2021 → Jul 2023 | cervical cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04679064 Comparator | Dec 2020 → Jan 2025 | ovarian cancer | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unknown | No outcome recorded |
| Phase 3 | NCT04421547 Comparator | Jun 2020 → Nov 2024 | malignant epithelial tumor of ovary | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Terminated | No outcome recorded |
| Phase 3 | NCT04209855 Comparator | Dec 2019 → Mar 2023 | fallopian tube carcinoma, malignant epithelial tumor of ovary, peritoneal carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04073550 Background | Oct 2019 → Jul 2021 | small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03949283 Comparator | Jul 2019 → Jun 2024 overdue | ovarian carcinoma | Cordgenics, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03126916 Background | May 2018 → Sep 2030 expected | neuroblastoma, nodular ganglioneuroblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT03088813 Comparator | Apr 2018 → Feb 2022 | small cell lung carcinoma | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT03061812 Comparator | Apr 2017 → Feb 2020 | small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02566993 Comparator | Aug 2016 → Feb 2020 | small cell lung carcinoma | PharmaMar | Completed | No outcome recorded |
| Phase 3 | NCT02665065 Comparator | Jun 2016 → Jun 2022 overdue | acute myeloid leukemia | Actinium Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02584478 Background | Dec 2015 → Oct 2024 | cervical carcinoma, endometrial carcinoma, fallopian tube carcinoma, ovarian carcinoma +1 | Advenchen Laboratories, LLC | Unknown | No outcome recorded |
| Phase 3 | NCT02481830 Comparator | Sep 2015 → Aug 2018 | lung cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02421588 Comparator | May 2015 → Oct 2018 | ovarian cancer | PharmaMar | Completed | No outcome recorded |
| Phase 3 | NCT02282020 Comparator | Feb 2015 → Oct 2018 | hereditary neoplastic syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02738346 Comparator | Jul 2013 → Jul 2017 | small cell lung carcinoma | University Hospital, Angers | Unknown | No outcome recorded |
| Phase 3 | NCT01849874 Comparator | Jun 2013 → Jan 2016 | fallopian tube serous adenocarcinoma, malignant ovarian serous tumor, primary peritoneal serous adenocarcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT01840943 Comparator | Jun 2013 → May 2014 | malignant epithelial tumor of ovary | Xian-Janssen Pharmaceutical Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT01684878 Background | Oct 2012 → Jan 2015 | ovarian cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01593228 Background | May 2012 → Sep 2016 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00976911 Background | Oct 2009 → Jul 2014 | ovarian cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00547651 Comparator | Sep 2007 → May 2011 | small cell lung carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00477282 Comparator | Aug 2007 → Jun 2013 | ovarian carcinoma | BioNumerik Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00437307 Comparator | Mar 2007 → Jul 2013 | ovarian carcinoma | North Eastern German Society of Gynaecological Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00041015 Comparator | Sep 2001 → Nov 2002 | small cell lung carcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00028743 Comparator | Aug 2001 → Mar 2008 | fallopian tube cancer, ovarian cancer, peritoneum cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05874401 Background | Oct 2023 → Oct 2027 expected | small cell lung carcinoma | Pharmacosmos A/S | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2000-11-02 | Gilead Sciences | Gilead Begins Phase II Study of NX 211, Investigational Compound for the Treatment of Patients with Topotecan Resistant Ovarian Cancer gilead.com ↗ |
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 458 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Topotecan | “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗428“Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on...” NCT04421547 ↗ “Study treatment in the arm A is left to the investigator appreciations. This may include immune checkpoint inhibitors, docetaxel, topotecan for primary lung tumors, and FOLFOX,...” NCT06937905 ↗ “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Liposomal Doxorubicin; * Docetaxel; *...” NCT03949283 ↗ “Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at...” NCT00739830 ↗ “There will be six groups: 1) combination with paclitaxel, 2) combination with topotecan, 3) combination with doxorubicin, 4) combination with 5-fluorouracil, folinic acid, and...” NCT06840886 ↗ “Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine.” NCT02282020 ↗ “Patients will recieve 3 cycles of carboplatin and gemcitabine followed by 3 cycles of taxol and carboplatin and then three cycles of adriamycin and topotecan.” NCT00157560 ↗ “The possible choices as defined by the protocol: * Paclitaxel * Gemcitabine * Pegylated liposomal doxorubicin (PLD) * Topotecan” NCT07546500 ↗ “Topotecan-Monotherapy Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Therapy in Patients With Recurrent Ovarian Cancer” NCT00312988 ↗ “Chemotherapy list: * Liposomal Doxorubicin; * Docetaxel; * Paclitaxel; * Carboplatin; * Cisplatin; * Gemcitabine; * Topotecan;” NCT03632798 ↗ “Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d” NCT01405235 ↗ “Topotecan: Intravenously infused on Days 1, 8, and 15 of each 4 - week treatment cycle at a daily dose of 4 mg/m².” NCT06990503 ↗ “Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days” NCT01047891 ↗ “Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol” NCT05266196 ↗ “Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;” NCT04055038 ↗ “Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d” NCT00170625 ↗ “Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets” NCT03987685 ↗ “Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)” NCT01849874 ↗ “Topotecan is administered by an ambulatory infusion pump for 72 hours each week.” NCT00002986 ↗ “Cyclophosphamide and topotecan are both FDA-approved chemotherapy drugs.” NCT02298348 ↗ “Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4)” NCT01342237 ↗ “Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days” NCT03651206 ↗ “Topoisomerase 1 inhibitor: Topotecan or Irinotecan” NCT03257267 ↗ “Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days” NCT02030184 ↗ “topotecan (4mg/m2 on D1,8,15 every 4 weeks)” NCT03699449 ↗ “topotecan, cyclophosphamide, and etoposide” NCT03042429 ↗ “Topotecan IV continuously over 72 hours.” NCT00053287 ↗ “Topotecan, Lurbinectedin, or Amrubicin” NCT07218146 ↗ “Thioguanine Topotecan HCl Trametinib” NCT02551718 ↗ “topotecan: 1.2 mg/m\^2 IV days 1-5” NCT01576692 ↗ “cyclophosphamide and/or topotecan” NCT03236857 ↗ “topotecan by intravenous infusion” NCT06692166 ↗ “topotecan oral capsules 1.1 mg/m2” NCT00390806 ↗ “Thiotepa, Topotecan, Toremifene” NCT02788201 ↗ “including topotecan (1.2 mg/m” NCT07230626 ↗ “topotecan(2mg/m2.d, d3-d5)” NCT06933394 ↗ “Hycamptin(R) (topotecan)” NCT00602667 ↗ “Drug: topotecan” NCT00316173 ↗ “Topotecan” NCT01703910 ↗ “Topotecan” NCT02665065 ↗ “Topotecan” NCT05421897 ↗ “topotecan” NCT07214779 ↗ |
| Known as | Evotopin | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Ff-10850 (liposomal topotecan) | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Hycamptamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Hycamptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00429559 ↗ |
| Known as | Hycamptin(R) (topotecan) | “Hycamptin(R) (topotecan)” NCT00602667 ↗ |
| Known as | Hycamtin | “Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes...” NCT00826891 ↗9“This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people...” NCT00316186 ↗ “Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown...” NCT01690598 ↗ “A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix” NCT00087126 ↗ “The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them.” NCT00276276 ↗ “The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.” NCT00267488 ↗ “A Pilot Study Of Hycamtin (Topotecan) And Thalomid (Thalidomide) In Patients With Recurrent Malignant Gliomas” NCT00014443 ↗ “Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg” NCT00918320 ↗ “Hycamtin (Topotecan)” NCT00770731 ↗ “Hycamtin (topotecan)” NCT00698516 ↗ |
| Known as | Hycamtin MS | “Topotecan (Hycamtin MS)” NCT00003415 ↗ |
| Known as | Nogitecan | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | nogitecan hydrochloride | “METHODS: Patients were randomized 1:1 to tisotumab vedotin or investigator-choice chemotherapy (topotecan [nogitecan hydrochloride], vinorelbine, gemcitabine, irinotecan, or...” PMID 41644383 ↗ Dec 2025 |
| Known as | NSC-609699 | “A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent...” NCT00276796 ↗6“Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).” NCT00002625 ↗ “A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix” NCT00087126 ↗ “Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer” NCT00005029 ↗ “A Phase II Study of Continuous 21 Day Infusion of Topotecan (NSC # 609699) in Children With Relapsed Solid Tumors” NCT00003745 ↗ “Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.” NCT00002705 ↗ “Topotecan, TOPO, NSC-609699.” NCT00002588 ↗ |
| Known as | NSC-641007 | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | NSC-759263 | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Potactasol | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | SK&F S-104864-A | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | SK-S-104864-A | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | SKF 104864 | “Topotecan (SKF 104864) With Recombinant GM-CSF (Sargramostim)” NCT00002950 ↗1“oral topotecan (SK&F-104864); lapatinib (GW572016)” NCT00682279 ↗ |
| Known as | TLI | “Topotecan Liposomes Injection (TLI)” NCT00765973 ↗ |
| Known as | TOPO | “Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).” NCT00002625 ↗ |
| Known as | Topotecan (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Topotecan - Hycamtin | “Topotecan - Hycamtin” NCT00610571 ↗ |
| Known as | Topotecan actavis | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Topotecan eagle | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Topotecan HCl | “Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.” NCT01840943 ↗ |
| Known as | Topotecan hospira | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | topotecan hydrochloride | “This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating...” NCT03896503 ↗56“Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6...” NCT05736952 ↗ “Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).” NCT00002625 ↗ “PURPOSE: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment.” PMID 19726073 ↗ Sep 2009 “Arm II (experimental): Patients receive N8 chemotherapy comprising topotecan hydrochloride IV continuously over 168 hours and cyclophosphamide IV over 1 hour on days 1-7” NCT00410631 ↗ “Patients receive topotecan hydrochloride IV, cyclophosphamide IV, and carboplatin IV over 8 hours on days -6 to -3.” NCT00652691 ↗ “Patients receive cyclophosphamide IV over 30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5” NCT00567567 ↗ “topotecan (topotecan hydrochloride) 0.6 mg/m\^2 administered IV once daily on days 1 to 5 of each cycle” NCT01266447 ↗ “Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8” NCT00541359 ↗ “Patients receive oral topotecan hydrochloride on days 1, 8, and 15 and carboplatin IV on day 1.” NCT00807079 ↗ “topotecan hydrochloride in treating patients with relapsed or refractory small cell lung cancer” NCT00521144 ↗ “intravenous (IV) topotecan hydrochloride (topotecan) on progression free survival (PFS)” NCT01803269 ↗ “Topotecan hydrochloride will be administered intravenously per prescribing information.” NCT06612151 ↗ “pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan hydrochloride).” NCT02357810 ↗ “Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and 15-19” NCT00389766 ↗ “topotecan hydrochloride for injection” NCT00057720 ↗ “Drug: topotecan hydrochloride” NCT00828139 ↗ “Drug: topotecan hydrochloride” NCT00033696 ↗ “Drug: topotecan hydrochloride” NCT00002734 ↗ “Drug: Topotecan Hydrochloride” NCT02569957 ↗ “Drug: topotecan hydrochloride” NCT00002587 ↗ “Drug: topotecan hydrochloride” NCT00287963 ↗ “Drug: topotecan hydrochloride” NCT00028925 ↗ “Drug: topotecan hydrochloride” NCT00006012 ↗ “Drug: topotecan hydrochloride” NCT00004055 ↗ “Drug: topotecan hydrochloride” NCT00098956 ↗ “Drug: topotecan hydrochloride” NCT00003745 ↗ “Drug: Topotecan Hydrochloride” NCT00588991 ↗ “Drug: topotecan hydrochloride” NCT00068484 ↗ “Drug: topotecan hydrochloride” NCT00109798 ↗ “Drug: topotecan hydrochloride” NCT00287859 ↗ “Drug: topotecan hydrochloride” NCT00006125 ↗ “topotecan hydrochloride” NCT00004006 ↗ |
| Known as | Topotecan teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | Topotecane | ChEMBL registry synonym — accepted as the source's own label CHEMBL84 ↗ |
| Known as | TPT | “This clinical trial is designed to explore the hypothesis that chronic administration of topotecan (TPT) inhibits Hypoxia Inducible factor 1alpha (HIF-1alpha) expression and...” NCT00117013 ↗3“daily 30-minute infusions of topotecan (TPT) for up to 12 consecutive days” PMID 11896112 ↗ Mar 2002 “To test the safety of the combination of ABT-888 and Topotecan (TPT)” NCT00553189 ↗ “Drug: topotecan (TPT)” NCT00325416 ↗ |
| Action | Inhibit | “a topoisomerase I inhibitor” NCT00001333 ↗ |
| Modality | Small molecule | “topotecan, a camptothecin analog” PMID 14586216 ↗ Nov 2003 |
| Route | Intrathecal | “Topotecan will be administered intrathecally” NCT00001333 ↗ |
| Target | HIF1A | “topotecan inhibits HIF-1alpha expression” NCT00117013 ↗ |